Nigel Birks Andrew Craig News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nigel birks andrew craig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nigel Birks Andrew Craig Today - Breaking & Trending Today

Investegate |Destiny Pharma PLC Announcements | Destiny Pharma PLC: Destiny Pharma Investor Presentation

About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. ....

Brighton And Hove , United Kingdom , Nigel Barnes Claes , Shaun Claydon , Nigel Birks Andrew Craig , Neil Clark , Strategic Communications , Wg Partners , Investor Meet Company , Destiny Pharma , Chief Executive Officer , Chief Financial Officer , Company Secretary , Cap Limited , Joint Broker , Kate Bannatyne , Charlie Beeson , Corporate Finance , Nigel Birks , Shabnam Bashir , Manel Mateus , Investegate Announcements , Investegate Company Announcements , Destiny Pharma Plc , Regulatory News Service , Regulatory News Service And ,

Investegate |Destiny Pharma PLC Announcements | Destiny Pharma PLC: Grant of Share Options

A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
1. Obtains access to the information in a personal capacity;
2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so; ....

Brighton And Hove , United Kingdom , City Of , Nigel Barnes Claes , Shaun Claydon , William Love , Nigel Birks Andrew Craig , Neil Clark , Jesus Gonzalez , Strategic Communications , London Stock Exchange , Wg Partners , Destiny Pharma , Term Incentive Plan , Chief Executive Officer , Chief Financial Officer , Company Secretary , Cap Limited , Joint Broker , Kate Bannatyne , Charlie Beeson , Corporate Finance , Nigel Birks , Shabnam Bashir , Manel Mateus , Market Abuse Regulation ,

Investegate |Destiny Pharma PLC Announcements | Destiny Pharma PLC: Destiny Pharma: Directors Dealings

Investegate announcements from Destiny Pharma PLC, Destiny Pharma: Directors Dealings ....

City Of , United Kingdom , Nick Rodgers , Nigel Barnes Claes , Shaun Claydon , Nigel Birks Andrew Craig , Neil Clark , Strategic Communications , London Stock Exchange , Wg Partners , Destiny Pharma Plc , Destiny Pharma , Stock Exchange , Chief Executive Officer , Chief Financial Officer , Company Secretary , Cap Limited , Joint Broker , Kate Bannatyne , Charlie Beeson , Corporate Finance , Nigel Birks , Shabnam Bashir , Manel Mateus , Market Abuse Regulation , Investegate Announcements ,

Destiny Pharma plc (via Public) / Update on the recently acquired NTCD-M3 programme

Update on the recently acquired NTCD-M3 programme
Destiny Pharma plc
( Destiny Pharma or the Company )
Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficileinfections
Brighton, United Kingdom - 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the prevention of C. difficileinfection (CDI) recurrence.
Following the successful fundraising of £10.4 million in November 2020 and completion of the acquisition of NTCD-M3, Destiny Pharma has commenced the work required to prepare for the Phase 3 clinical study that is scheduled to start in 2022. ....

United Kingdom , Brighton And Hove , Nigel Barnes Claes , Shaun Claydon , Nigel Birks Andrew Craig , Dale Gerding , Neil Clark , Strategic Communications , Wg Partners , Journal Of The American Medical Association Gerding , Destiny Pharma , Professor Dale Gerding , Scientific Advisory Board , Bill Love , Chief Scientific Officer , Chief Executive Officer , Chief Financial Officer , Company Secretary , Cap Limited , Kate Bannatyne , Charlie Beeson , Corporate Finance , Nigel Birks , Shabnam Bashir , American Medical Association , ஒன்றுபட்டது கிஂக்டம் ,